A qualitative study of patients' goals and expectations for self-management of COPD
Background: Chronic obstructive pulmonary disease (COPD) is an illness that affects patients
on multiple levels, both physically and psychologically. While there is a growing body of …
on multiple levels, both physically and psychologically. While there is a growing body of …
[HTML][HTML] Safety and efficacy of ceftolozane/tazobactam versus meropenem in neonates and children with complicated urinary tract infection, including pyelonephritis: a …
…, MG Johnson, J Lonchar, FH Su… - The Pediatric …, 2023 - journals.lww.com
Background: Ceftolozane/tazobactam, a cephalosporin-β-lactamase inhibitor combination,
active against multidrug-resistant Gram-negative pathogens, is approved for treatment of …
active against multidrug-resistant Gram-negative pathogens, is approved for treatment of …
Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III)
…, MB Dorr, G Winchell, FH Su… - Journal of the …, 2023 - academic.oup.com
Background Therapies to prevent recurrence of Clostridioides difficile infection (CDI) in pediatric
patients are needed. Bezlotoxumab is a fully human monoclonal antibody approved for …
patients are needed. Bezlotoxumab is a fully human monoclonal antibody approved for …
Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without …
…, D Fernsler, JJ Li, A Grandhi, H Liu, FH Su… - The Lancet …, 2017 - thelancet.com
Background New hepatitis C virus (HCV) therapies with pan-genotypic efficacy are needed.
The goals of part A of C-CREST-1 and C-CREST-2 were to compare the efficacies of two …
The goals of part A of C-CREST-1 and C-CREST-2 were to compare the efficacies of two …
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study
…, D Brown, E Asante‐Appiah, FH Su… - Liver …, 2020 - Wiley Online Library
Background & Aims Hepatitis C virus (HCV) genotype (GT) 4 infection is prevalent in sub‐Saharan
Africa and the Middle East, particularly in Egypt. This study evaluated the safety and …
Africa and the Middle East, particularly in Egypt. This study evaluated the safety and …
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with …
…, D Fernsler, JJ Li, A Grandhi, H Liu, FH Su… - The Lancet …, 2017 - thelancet.com
Background There is a need for hepatitis C virus (HCV) therapies with excellent efficacy
across genotypes and in diverse populations. Part A of the C-CREST-1 and C-CREST-2 trials …
across genotypes and in diverse populations. Part A of the C-CREST-1 and C-CREST-2 trials …
[HTML][HTML] Geographic disparity in COPD hospitalization rates among the Texas population
BE Jackson, S Suzuki, K Lo, F Su, KP Singh… - Respiratory …, 2011 - Elsevier
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity
and mortality caused by cigarette smoking and other environmental exposures. While …
and mortality caused by cigarette smoking and other environmental exposures. While …
[HTML][HTML] Safety and efficacy of ceftolozane/tazobactam plus metronidazole versus meropenem from a phase 2, randomized clinical trial in pediatric participants with …
…, N Dementieva, J Lonchar, FH Su… - The Pediatric …, 2023 - journals.lww.com
Background: Ceftolozane/tazobactam, a cephalosporin–β-lactamase inhibitor combination,
is approved for the treatment of complicated urinary tract infections and complicated intra-…
is approved for the treatment of complicated urinary tract infections and complicated intra-…
Subgroup analysis of phase 2 study of ceftolozane/tazobactam in neonates and young infants with pyelonephritis
…, JA Huntington, P Wickremasingha, FH Su… - Microbiology …, 2023 - Am Soc Microbiol
Ceftolozane/tazobactam is approved for the treatment of patients from birth to <18 y old with
complicated urinary tract infections (cUTI). This post hoc analysis evaluated the safety, …
complicated urinary tract infections (cUTI). This post hoc analysis evaluated the safety, …
Surface plasmon resonance phase-shift interferometry: real-time DNA microarray hybridization analysis
SJ Chen, YD Su, FM Hsiu, CY Tsou… - Journal of Biomedical …, 2005 - spiedigitallibrary.org
Surface plasmon resonance (SPR) phase-shift interferometry (PSI) is a novel technique which
combines SPR and modified Mach–Zehnder PSI to measure the spatial phase variation …
combines SPR and modified Mach–Zehnder PSI to measure the spatial phase variation …